Form 8-K - Current report:
SEC Accession No. 0001641172-25-026864
Filing Date
2025-09-08
Accepted
2025-09-08 16:30:39
Documents
12
Period of Report
2025-09-04
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 37412
  Complete submission text file 0001641172-25-026864.txt   202981

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE qlgn-20250904.xsd EX-101.SCH 3008
3 XBRL LABEL FILE qlgn-20250904_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE qlgn-20250904_pre.xml EX-101.PRE 22354
14 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3692
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 251300437
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)